Phase 1/2a study of (177)Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

For patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20–based immunochemotherapy or develop relapsed or refractory disease, there remains a significant unmet clinical need for new therapeutic approaches to improve outcomes and quality of life. (177)Lu-lilotomab satetraxetan is a n...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Kolstad, Arne, Illidge, Tim, Bolstad, Nils, Spetalen, Signe, Madsbu, Ulf, Stokke, Caroline, Blakkisrud, Johan, Løndalen, Ayca, O'Rourke, Noelle, Beasley, Matthew, Jurczak, Wojciech, Fagerli, Unn-Merete, Kaščák, Michal, Bayne, Mike, Obr, Aleš, Dahle, Jostein, Rojkjaer, Lisa, Pascal, Veronique, Holte, Harald
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2020
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7479948/
https://ncbi.nlm.nih.gov/pubmed/32877524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002583
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares